Skip to main content
Top
Published in: Dermatology and Therapy 1/2016

Open Access 01-03-2016 | Brief Report

Amorolfine 5% Nail Lacquer Exhibits Potent Antifungal Activity Compared to Three Acid-Based Devices Indicated for the Treatment of Onychomycosis: An In Vitro Nail Penetration Assay

Authors: Mahmoud Ghannoum, Karine Sevin, Marlis Sarkany

Published in: Dermatology and Therapy | Issue 1/2016

Login to get access

Abstract

Introduction

Onychomycosis is the most common infectious disease involving nails. The aim of this study was to evaluate the antifungal activity of amorolfine 5% nail lacquer and three different acid-based medical devices indicated in the treatment of onychomycosis using an in vitro nail penetration assay.

Methods

Four products were tested in vitro: (a) amorolfine 5% nail lacquer; (b) ethyl lactate and acetic acid; (c) citric acid and urea; (d) ethyl lactate, glycerin, lactic acid, and citric acid. Test products were applied to healthy human cadaver nails and allowed to dry. Disks were cut from each piece of nail and placed on seeded agar plates of Trichophyton rubrum. Following incubation at 30 °C, zones of inhibition were measured.

Results

Amorolfine-treated nails exhibited inhibitory activity against T. rubrum with a mean zone of inhibition of 59.2 mm in diameter. In contrast, all three acid-based medical devices and the untreated controls showed no zones of inhibition (mean effective zones of 0 mm).

Conclusion

In this in vitro nail penetration model, head-on, comparative study, we showed that amorolfine 5% nail lacquer possesses potent antifungal activity, whereas no antifungal activity was detected for three commercially available acid-based medical devices under identical assay conditions.

Funding

Galderma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chacon A, Franca K, Fernandez A, Nouri K. Psychosocial impact of onychomycosis: a review. Int J Dermatol. 2013;52(11):1300–7.CrossRefPubMed Chacon A, Franca K, Fernandez A, Nouri K. Psychosocial impact of onychomycosis: a review. Int J Dermatol. 2013;52(11):1300–7.CrossRefPubMed
2.
go back to reference Chan HH, Wong ET, Yeung CK. Psychosocial perception of adults with onychomycosis: a blinded, controlled comparison of 1,017 adult Hong Kong residents with or without onychomycosis. Biopsychosoc Med. 2014;8:15.CrossRefPubMedPubMedCentral Chan HH, Wong ET, Yeung CK. Psychosocial perception of adults with onychomycosis: a blinded, controlled comparison of 1,017 adult Hong Kong residents with or without onychomycosis. Biopsychosoc Med. 2014;8:15.CrossRefPubMedPubMedCentral
3.
go back to reference Effendy I, Lecha M. Feuilhade de Chauvin M, Di Chiacchio N, Baran R; European Onychomycosis Observatory. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol. 2005;19(Suppl 1):8–12.CrossRefPubMed Effendy I, Lecha M. Feuilhade de Chauvin M, Di Chiacchio N, Baran R; European Onychomycosis Observatory. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol. 2005;19(Suppl 1):8–12.CrossRefPubMed
4.
go back to reference Elsayed MM. Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective. J Control Release. 2015;199:132–44.CrossRefPubMed Elsayed MM. Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective. J Control Release. 2015;199:132–44.CrossRefPubMed
5.
go back to reference Mensing H, Polak-Wyss A, Splanemann V. Determination of the subungual antifungal activity of Amorolfine after 1 month’s treatment in patients with oncychomycosis: comparison of two nail lacquer formulations. Clin Exp Dermatol. 1992;17(suppl 1):29–32.CrossRefPubMed Mensing H, Polak-Wyss A, Splanemann V. Determination of the subungual antifungal activity of Amorolfine after 1 month’s treatment in patients with oncychomycosis: comparison of two nail lacquer formulations. Clin Exp Dermatol. 1992;17(suppl 1):29–32.CrossRefPubMed
7.
go back to reference Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol. 1992;17 Suppl 1:44–9.CrossRefPubMed Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol. 1992;17 Suppl 1:44–9.CrossRefPubMed
8.
go back to reference Macura AB. In vitro susceptibility of dermatophytes to antifungal drugs: a comparison of two methods. Int J Dermatol. 1993;32(7):533–6.CrossRefPubMed Macura AB. In vitro susceptibility of dermatophytes to antifungal drugs: a comparison of two methods. Int J Dermatol. 1993;32(7):533–6.CrossRefPubMed
9.
go back to reference Clinical Laboratory Standards Institute—Proposed Guideline Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard, Eleventh Edition, M02-A11. 2012;32(1). Clinical Laboratory Standards Institute—Proposed Guideline Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard, Eleventh Edition, M02-A11. 2012;32(1).
10.
go back to reference Neubert RH, Gensbügel C, Jäckel A, Wartewig S. Different physicochemical properties of antimycotic agents are relevant for penetration into and through human nails. Pharmazie. 2006;61(7):604–7.PubMed Neubert RH, Gensbügel C, Jäckel A, Wartewig S. Different physicochemical properties of antimycotic agents are relevant for penetration into and through human nails. Pharmazie. 2006;61(7):604–7.PubMed
11.
go back to reference Sigurgeirsson B, Ghannoum MA, Osman-Ponchet H, Kerrouche N, Sidou F. Application of cosmetic nail varnish does not affect the antifungal efficacy of amorolfine 5% nail lacquer in the treatment of distal subungual toenail onychomycosis: results of a randomised active-controlled study and in vitro assays. Mycoses. (2016 in press). Sigurgeirsson B, Ghannoum MA, Osman-Ponchet H, Kerrouche N, Sidou F. Application of cosmetic nail varnish does not affect the antifungal efficacy of amorolfine 5% nail lacquer in the treatment of distal subungual toenail onychomycosis: results of a randomised active-controlled study and in vitro assays. Mycoses. (2016 in press).
12.
go back to reference Schaller M, Borelli C, Berger U, et al. Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection. Med Mycol. 2009;47(7):753–8.CrossRefPubMed Schaller M, Borelli C, Berger U, et al. Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection. Med Mycol. 2009;47(7):753–8.CrossRefPubMed
13.
go back to reference Martinez-Rossi NM, Persinoti GF, Peres NT, Rossi A. Role of pH in the pathogenesis of dermatophytoses. Mycoses. 2012;55(5):381–7.CrossRefPubMed Martinez-Rossi NM, Persinoti GF, Peres NT, Rossi A. Role of pH in the pathogenesis of dermatophytoses. Mycoses. 2012;55(5):381–7.CrossRefPubMed
14.
go back to reference Hultenby K, Chryssanthou E, Klingspor L, Rensfeldt K, Strömbeck L, Faergemann J. The effect of K101 Nail Solution on Trichophyton rubrum and Candida albicans growth and ultrastructure. Mycoses. 2014;57(10):630–8.CrossRefPubMed Hultenby K, Chryssanthou E, Klingspor L, Rensfeldt K, Strömbeck L, Faergemann J. The effect of K101 Nail Solution on Trichophyton rubrum and Candida albicans growth and ultrastructure. Mycoses. 2014;57(10):630–8.CrossRefPubMed
15.
go back to reference Yazdanparast SA, Barton RC. Arthroconidia production in Trichophyton rubrum and a new ex vivo model of onychomycosis. J Med Microbiol. 2006;55(Pt 11):1577–81.CrossRefPubMed Yazdanparast SA, Barton RC. Arthroconidia production in Trichophyton rubrum and a new ex vivo model of onychomycosis. J Med Microbiol. 2006;55(Pt 11):1577–81.CrossRefPubMed
16.
go back to reference Cheung YY, Lee S, Hui M, Luk T. Effect of pH on fungal growth: problems with using vinegar (5% acetic acid) in treating superficial fungal infections. Hong Kong J Dermatol Venereol. 2014;2:57–64. Cheung YY, Lee S, Hui M, Luk T. Effect of pH on fungal growth: problems with using vinegar (5% acetic acid) in treating superficial fungal infections. Hong Kong J Dermatol Venereol. 2014;2:57–64.
17.
go back to reference Lee WJ, Park KH, Song CH, Lee S-J, Kim DW. Efficacy of trichloroacetic acid in patients with toenail onychomycosis: pilot study with 14 patients. Korean J Medical Mycology. 2014;19(2):25–30.CrossRef Lee WJ, Park KH, Song CH, Lee S-J, Kim DW. Efficacy of trichloroacetic acid in patients with toenail onychomycosis: pilot study with 14 patients. Korean J Medical Mycology. 2014;19(2):25–30.CrossRef
18.
go back to reference Faergemann J, Swanbeck G. Treatment of onychomycosis with a propylene glycol–urea–lactic acid solution. Mycoses. 1989;32(10):536–40. Faergemann J, Swanbeck G. Treatment of onychomycosis with a propylene glycol–urea–lactic acid solution. Mycoses. 1989;32(10):536–40.
19.
go back to reference Faergemann J, Gullstrand S, Rensfeldt K. Early and visible improvements after application of K101 in the appearance of nails discoloured and deformed by onychomycosis. J Cosmet Dermatol Sci Appl. 2011;1:59–63. Faergemann J, Gullstrand S, Rensfeldt K. Early and visible improvements after application of K101 in the appearance of nails discoloured and deformed by onychomycosis. J Cosmet Dermatol Sci Appl. 2011;1:59–63.
20.
go back to reference Emtestam L, Kaaman T, Rensfeldt K. Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study. Mycoses. 2012;55(6):532–40.CrossRefPubMed Emtestam L, Kaaman T, Rensfeldt K. Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study. Mycoses. 2012;55(6):532–40.CrossRefPubMed
Metadata
Title
Amorolfine 5% Nail Lacquer Exhibits Potent Antifungal Activity Compared to Three Acid-Based Devices Indicated for the Treatment of Onychomycosis: An In Vitro Nail Penetration Assay
Authors
Mahmoud Ghannoum
Karine Sevin
Marlis Sarkany
Publication date
01-03-2016
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 1/2016
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-016-0093-x

Other articles of this Issue 1/2016

Dermatology and Therapy 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine